Chad A. Landmon
Partner
Email Page
Photo of Chad A. Landmon
TEL CT - 860.275.8170
TEL2 DC - 202.721.5415
FAX CT - 860.275.8101
FAX2 DC - 202.912.4701
clandmon@axinn.com, Connecticut
Download V-Card

Chad Landmon practices primarily in the areas of patent and other intellectual property litigation and counseling and food and drug law, with a focus on the life sciences. Mr. Landmon is Chair of Axinn, Veltrop & Harkrider LLP's Intellectual Property and FDA Practice Groups.

Mr. Landmon litigates intellectual property cases in federal and state courts across the country, as well as in arbitration proceedings, involving numerous industries, including pharmaceuticals, printing and packaging, power tools, and many others. Representative examples of recent patent infringement cases handled include: Roche Palo Alto LLC v. Endo Pharmaceuticals Inc., No. 10-00261 (D. Del.); Genzyme Corporation v. Endo Pharmaceuticals Inc., No. 09-02589 (D. Md.); sanofi-aventis v. Actavis South Atlantic LLC, No. 07-572 (D. Del.); Purdue Pharma L.P. v. Actavis Totowa LLC, No. 07-3972 (S.D.N.Y.); Shire LLC v. Actavis, Inc., No. 07-00718 (D. Md.); Adams Respiratory Therapeutics, Inc. v. URL/Mutual Pharmaceutical Cos., No. 06-4418 (E.D. Pa.); Cushion Technologies, LLC v. Fila USA, Inc., No. 06-347 (E.D. Tx.); Eisai Co., Ltd. v. URL/Mutual Pharmaceutical Cos., No. 06-03613-HAA-MF (D.N.J.); Whelen Engineering Co., Inc. v. Star Headlight & Lantern Co., Inc., No. 06-0299 (JCH) (D.Conn.); Arthur Blank & Co. v. Moore North America, Inc., No. 02-2282 (W.D. Tenn.); Rexon Industrial Corp. v. Ryobi Technologies, 02-1264 (D. Conn.).

A significant portion of Mr. Landmon’s practice is spent in the firm’s FDA and BioMedical Practice Groups, in which he provides counseling and litigation services relating to patent, FDA and antitrust issues involving the development and marketing of new and generic drug products and the regulation of tobacco products. The FDA matters involve numerous issues relating to the Hatch-Waxman Amendments, including marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling and other issues relating to the FDA approval process. Mr. Landmon has petitioned FDA and litigated disputes involving a variety of issues, including new chemical entity exclusivity, the generic exclusivity period and pediatric exclusivity. Representative examples of recent litigation involving FDA issues includes: Actavis Elizabeth LLC v. FDA, No. 09-362 (D.D.C.); Mylan Laboratories, Inc. v. FDA, No. 07-579 (D. D.C.) (representing third-party intervenor); Ranbaxy Labs, Ltd. v. FDA, No. 04-0869 (D.D.C.) (representing third-party intervenor); Purepac Pharmaceutical Co. v. FDA, No. 03-2282 (D.D.C.). Mr. Landmon has also handled Lanham Act cases relating to false advertising allegations, including in a case in which the firm obtained the dismissal of such claims based upon an argument that the claims were preempted by FDA law. See Wyeth v. Sun Pharmaceutical Indus. Ltd., 2010 U.S. Dist. LEXIS 18180, Dkt. No. 09-11726 (E.D. Mich. March 2, 2010). Mr. Landmon frequently speaks and writes about issues relating to FDA law and pharmaceutical patent litigation. He also serves on the Editorial Advisory Board of Generic Line, a publication of FDAnews.

Mr. Landmon has an active intellectual property counseling practice, in which he evaluates patent, trademark and trade secret claims. He is often involved with the product development process, assisting clients in navigating around the intellectual property rights of competitors and in designing their own patent strategies. In the course of this practice, Mr. Landmon provides advice and services to clients regarding the acquisition, management and enforcement of intellectual property portfolios. He also prepares freedom-to-operate opinions and opinions relating to the infringement and validity of patents.

Mr. Landmon also participates in matters involving the intersection of the antitrust and patent laws, including issues arising from the settlement of patent and Hatch-Waxman exclusivity disputes, the licensing of critical technology and the formulation of joint development relationships. In addition to providing advice regarding such issues, Mr. Landmon has also represented clients during FTC investigations involving such agreements.

Mr. Landmon has also been involved with commercial litigation and arbitration involving a variety of complex contract and tort law issues.

Bar Admissions

Articles & Newsletters

Speaking Engagements & Seminars

Professional Activities